Lincoln Pharmaceuticals Reports Strong PAT and EPS Growth Amid Non-Operating Income Concerns in August 2025

Lincoln Pharmaceuticals, a microcap player in the Pharmaceuticals & Biotechnology industry, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 7, 2025, indicate a notable adjustment in evaluation, with the score moving to 0 from -6 over the past three months.
The financial data reveals several positive aspects for Lincoln Pharmaceuticals. The Profit After Tax (PAT) reached Rs 27.68 crore, marking the highest figure in the last five quarters, suggesting a favorable near-term trend. Additionally, the Earnings per Share (EPS) also peaked at Rs 13.82 during this period, reflecting an increase in profitability and enhanced earnings for shareholders. Furthermore, the Debtors Turnover Ratio improved to 3.75 times, indicating that the company has been effective in settling its debts more swiftly.

Conversely, there are areas of concern highlighted in the financial results. The Non-Operating Income constituted 43.15% of Profit Before Tax (PBT), suggesting a reliance on income from non-business activities, which may not be sustainable in the long run. This income also reached its highest level at Rs 15.27 crore in the last five quarters, raising questions about the sustainability of such revenue streams.

For further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.